Tocilizumab effectiveness in paediatric non-infectious uveitis: data from the International AIDA Network Registries on ocular inflammatory disorders

To describe tocilizumab (TCZ) effectiveness in 15 children with refractory non-infectious uveitis. Reported outcomes are the number of relapses before and after treatment, steroid-sparing effect and drug retention rate. Macular oedema, fluorangiographic findings and ocular complications are also reported.The mean number of ocular relapses significantly decreased from 314 per 100 eyes/year to 106 per 100 eyes/year (p=0.016). A significant steroid-sparing effect was detected (p=0.037). TCZ drug survival was 77.4% at 6 months, followed by 61.9% at 12, 24 and 36 months of follow-up. Macular oedema and retinal vasculitis resolved in all affected eyes.

Authors

Institutions

Publication Details

Journal
British Journal of Ophthalmology
Published
2025-05-24
DOI
https://doi.org/10.1136/bjo-2025-327410
Citations
4
Primary Topic
Ocular Diseases and Behçet’s Syndrome
Type
article
Field-Weighted Citation Impact
6.83
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Tocilizumab effectiveness in paediatric non-infectious uveitis: data from the International AIDA Network Registries on ocular inflammatory disorders

Bruno Frediani, Maria Pia Paroli, Francesca Minoia, Emanuela Del Giudice et al.
4 citations
British Journal of Ophthalmology
Ocular Diseases and Behçet’s Syndrome
6.83
article

Tocilizumab effectiveness in paediatric non-infectious uveitis: data from the International AIDA Network Registries on ocular inflammatory disorders

Bruno Frediani, Maria Pia Paroli, Francesca Minoia, Emanuela Del Giudice, Antonio Vitale, Abdurrahman Tufan, Edoardo Biancalana, Silvana Guerriero, Luca Cantarini, Soad Hashad, Alejandra de‐la‐Torre, Saverio La Bella, Jurgen Sota, Claudia Fabiani, Sulaiman M. Al‐Mayouf, Luciana Breda, Juanita Cardona-López, María José Altamar-García
article en
4 citations

Abstract

To describe tocilizumab (TCZ) effectiveness in 15 children with refractory non-infectious uveitis. Reported outcomes are the number of relapses before and after treatment, steroid-sparing effect and drug retention rate. Macular oedema, fluorangiographic findings and ocular complications are also reported.The mean number of ocular relapses significantly decreased from 314 per 100 eyes/year to 106 per 100 eyes/year (p=0.016). A significant steroid-sparing effect was detected (p=0.037). TCZ drug survival was 77.4% at 6 months, followed by 61.9% at 12, 24 and 36 months of follow-up. Macular oedema and retinal vasculitis resolved in all affected eyes.

British Journal of OphthalmologyVol. 109(10)
Alfaisal University (SA), University of Tripoli (LY), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT), University of Chieti-Pescara (IT), Azienda Ospedaliero-Universitaria Careggi (IT), Azienda Ospedaliera Universitaria Senese (IT), University of Bari Aldo Moro (IT), Sapienza University of Rome (IT), Universidad del Rosario (CO), Gazi University (TR)
Good health and well-being
Openalex Percentile: Top 3%
Ocular Diseases and Behçet’s Syndrome
6.83
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.